{"product_id":"shph-five-forces","title":"(SHPH) Shuttle Pharmaceuticals Holdings, Inc. Porters Five Forces Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eElevate Your Analysis with the Complete Porter's Five Forces Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Shuttle Pharmaceuticals Holdings, Inc. Porter's Five Forces Analysis helps you understand the competitive pressures shaping the company’s market position and profitability. This page already shows a real preview of the report, so you can review the content before buying the full ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSuppliers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized active ingredient inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShuttle Pharmaceuticals Holdings, Inc. faces high supplier power because its pipeline needs niche active ingredients, including halogenated pyrimidines and injectable radiosensitizers, that must meet strict purity, stability, and regulatory specs. Only a small group of vendors can make these inputs, so they can push on price, quality, and lead times. For a company with limited scale, that dependence raises cost and supply risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract manufacturing dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShuttle Pharmaceuticals Holdings, Inc. likely depends on contract development and manufacturing organizations for clinical and future commercial supply, so suppliers can hold strong leverage. For small biotech firms, moving to a new manufacturer can take months of validation and comparability work, and sterile injectable scale-up raises the risk and cost further. That makes contract manufacturers a key bottleneck in 2025\/2026.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Suppliers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial service bottlenecks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShuttle Pharmaceuticals relies on specialized CROs, imaging teams, and lab partners to run oncology trials, and that vendor base is thin. In 2025, oncology still made up about 40% of all clinical-trial starts, but experienced radiation-oncology and rare-tumor vendors remain scarce, so suppliers can push up fees and lock in schedules.\u003c\/p\u003e\n\u003cp\u003eThat scarcity gives clinical service providers more pricing power and can slow enrollment, site activation, and data readouts. For a small biotech like Shuttle Pharmaceuticals, even one delayed trial can raise burn and extend the path to value creation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and quality constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory and quality rules keep supplier power high for Shuttle Pharmaceuticals Holdings, Inc.: FDA and cGMP compliance narrows the field, and a failed audit can push replacement timelines into months. The FDA logged 114 drug shortage entries in 2025, showing how tight pharma supply can become when quality or continuity breaks. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFewer qualified suppliers\u003c\/li\u003e\n\u003cli\u003eLong audit and re-approval cycles\u003c\/li\u003e\n\u003cli\u003eEstablished vendors gain leverage\u003c\/li\u003e\n\u003cli\u003eSupply failures can halt batches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLimited raw-material alternatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLimited raw-material alternatives raise supplier power for Shuttle Pharmaceuticals Holdings, Inc. because some oncology inputs cannot be swapped without changing the formulation or trial design. With only a few qualified sources, suppliers can push price, lead times, and minimum-order terms harder, which matters most when late-stage clinical continuity depends on the same material lot.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew qualified sources mean weaker pricing leverage.\u003c\/li\u003e\n\u003cli\u003eInput changes can disrupt trial design.\u003c\/li\u003e\n\u003cli\u003eLate-stage continuity makes switching costly.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShuttle Pharma Faces Tight Supplier Power in a Strained 2025 Supply Chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eShuttle Pharmaceuticals Holdings, Inc. faces high supplier power because only a few qualified vendors can supply its niche oncology inputs and clinical services, and switching can take months of validation. FDA cGMP rules narrow the field further, while 2025 FDA drug shortage entries hit 114, showing tight pharma supply.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA drug shortages\u003c\/td\u003e\n\u003ctd\u003e114 entries in 2025\u003c\/td\u003e\n\u003ctd\u003eSignals tight supply\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical-trial starts\u003c\/td\u003e\n\u003ctd\u003eOncology ~40% in 2025\u003c\/td\u003e\n\u003ctd\u003eSpecialist vendors stay scarce\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSwitching cost\u003c\/td\u003e\n\u003ctd\u003eMonths of revalidation\u003c\/td\u003e\n\u003ctd\u003eRaises supplier leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAssesses Shuttle Pharmaceuticals Holdings, Inc.’s competitive pressures, supplier and buyer power, substitutes, and entry risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot competitive pressure on Shuttle Pharmaceuticals with a clear, easy-to-use Five Forces snapshot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a traceable source trail for Shuttle Pharmaceuticals Holdings, Inc., helping validate assumptions and speed confident investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomers Bargaining Power\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospitals and oncology centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHospitals, cancer centers, and radiation oncology practices are the main buyers, and they are highly evidence-driven, so they can block adoption fast if Shuttle Pharmaceuticals Holdings, Inc.'s data on efficacy, safety, or workflow is weak.\u003c\/p\u003e\n\u003cp\u003eThat matters because U.S. hospital care reached about $1.5 trillion in 2023, so even small reimbursement or protocol issues can sway purchasing decisions.\u003c\/p\u003e\n\u003cp\u003eTheir leverage is meaningful: one payer policy shift or clinical guideline change can move demand across many sites at once.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePayer reimbursement pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEven if clinicians like Shuttle Pharmaceuticals Holdings, Inc.'s drug, about 90% of U.S. prescriptions are paid by insurers or government programs, so reimbursement can make or break uptake. If the therapy does not show clear clinical gain and lower total cost, payers can block access or force deep discounts. That weakens customer pull and cuts Shuttle Pharmaceuticals Holdings, Inc.'s pricing power.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician adoption thresholds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncologists rarely change protocols without hard proof, and drug adoption usually waits for strong phase 3 data after the 3-step clinical path. Shuttle Pharmaceuticals Holdings, Inc. is still in clinical phases, so buyers can delay commitment and compare safety and efficacy results first. That wait shifts pricing and timing power to physicians and hospital buyers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLimited initial customer base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShuttle Pharmaceuticals Holdings, Inc. faces a limited initial customer base because its addressable market is concentrated in specialized cancer treatment institutions, not broad hospital buyers. In pilot launches and early commercialization, even a few early adopters can matter a lot, so those buyers can push harder on price, contract terms, and trial support.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFew early buyers raise bargaining power.\u003c\/li\u003e\n\u003cli\u003eSpecialty oncology centers shape adoption.\u003c\/li\u003e\n\u003cli\u003ePilot deals can set pricing pressure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProtocol and formulary barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHospitals often force new oncology drugs through formulary review, protocol approval, and tumor-board consensus before use, so Shuttle Pharmaceuticals Holdings, Inc. faces a slow sales cycle. These gatekeepers can ask for discounts, outcomes data, or risk-sharing terms, which lifts buyer power and delays revenue conversion. For a pre-commercial developer, even a few extra months in approval can push cash burn before any meaningful uptake.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFormulary review delays adoption.\u003c\/li\u003e\n\u003cli\u003eGatekeepers demand lower net prices.\u003c\/li\u003e\n\u003cli\u003eOutcomes data can be required.\u003c\/li\u003e\n\u003cli\u003eRisk-sharing shifts value to buyers.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Buyer Power Limits Pricing for Shuttle Pharmaceuticals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBuyer power is high because Shuttle Pharmaceuticals Holdings, Inc. sells to a narrow set of hospitals and cancer centers that can delay adoption until phase 3 proof, formulary approval, and reimbursement are clear.\u003c\/p\u003e\n\u003cp\u003eThat leverage is stronger in oncology, where about 90% of U.S. prescriptions are insurer or government paid, so payers can force discounts or block access if value is not obvious.\u003c\/p\u003e\n\u003cp\u003eWith U.S. hospital care at about $1.5 trillion in 2023, even small protocol or payer changes can shift demand across many sites.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e90% paid by insurers\/government\u003c\/td\u003e\n\u003ctd\u003eHigh reimbursement leverage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e$1.5T U.S. hospital care\u003c\/td\u003e\n\u003ctd\u003eBig spend, but concentrated buyers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eSame Document Delivered\u003c\/span\u003e\u003cbr\u003eShuttle Pharmaceuticals Holdings, Inc. Porter's Five Forces Analysis\u003c\/h2\u003e\n\u003cp\u003eThis preview shows the exact Shuttle Pharmaceuticals Holdings, Inc. Porter's Five Forces Analysis you'll receive after purchase—no edits, no placeholders, just the final document. You’re viewing the complete, professionally formatted file, ready to download and use immediately. Once payment is complete, you’ll get instant access to this same analysis, exactly as shown here.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRivalry Among Competitors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDense oncology innovation field\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShuttle Pharmaceuticals Holdings, Inc. faces intense rivalry in oncology, where more than 1,000 cancer drugs are in clinical development worldwide and large firms keep funding new platforms. Even with a radiosensitizer focus, it still competes for trial sites, patients, and investor capital. In a field with so many active programs, scarce development resources can shift fast to better-funded peers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBig pharma competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBig pharma rivalry is intense because leaders like Pfizer posted $63.6 billion in 2024 revenue and Merck $64.2 billion, giving them far deeper pipelines, cash, and launch scale than Shuttle Pharmaceuticals Holdings, Inc. They can move combination therapies, targeted agents, and radiation adjuncts faster once demand is proven. That scale can squeeze pricing, trial access, and physician attention for a small biotech.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Rivalry-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCompeting treatment modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShuttle Pharmaceuticals Holdings, Inc. faces rivalry from immunotherapy, targeted therapy, surgery, chemotherapy, and better radiation protocols, not just direct drug peers. Radiation is already used in about half of all cancer cases, so Shuttle must prove added benefit against strong standard options. With oncology drug sales still dominated by big classes like immuno-oncology and targeted therapy, its clinical case can be harder to win.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClinical data race\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eShuttle Pharmaceuticals Holdings, Inc. faces fierce rivalry because in biotech, the first credible efficacy and safety readout can decide who gets licensing deals, partners, and trial momentum. A single strong Phase 1\/2 update can shift investor attention fast, while late or mixed data can cut deal value to near zero. That makes even small firms race on clinical proof, not just science.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFirst data can win partners.\u003c\/li\u003e\n\u003cli\u003eSafety and efficacy drive adoption.\u003c\/li\u003e\n\u003cli\u003eLate readouts weaken bargaining power.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHigh failure and restart rates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOncology rivalry stays volatile because most programs fail before approval: roughly 90% of cancer drugs entering clinical testing never reach market, and only about 1 in 10 makes it from Phase 1 to approval. When a rival asset fails, firms often restart around the same indication, so Shuttle Pharmaceuticals Holdings, Inc. has to win on data, not just a science story.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~90% of oncology programs fail\u003c\/li\u003e\n\u003cli\u003e~10% reach approval\u003c\/li\u003e\n\u003cli\u003eSetbacks trigger fast restarts\u003c\/li\u003e\n\u003cli\u003eData beats narrative\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShuttle Faces Brutal Oncology Competition\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCompetitive rivalry is high for Shuttle Pharmaceuticals Holdings, Inc. because oncology is crowded, capital-heavy, and data-driven. Big peers like Pfizer ($63.6B 2024 revenue) and Merck ($64.2B) can outspend, and about 90% of oncology programs still fail before approval. Shuttle must win on clear trial data, not just a niche radiosensitizer story.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePfizer revenue\u003c\/td\u003e\n\u003ctd\u003e$63.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMerck revenue\u003c\/td\u003e\n\u003ctd\u003e$64.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology failure rate\u003c\/td\u003e\n\u003ctd\u003e~90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Customers-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSubstitutes Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard radiation alone\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandard radiation alone is the clearest substitute for Shuttle Pharmaceuticals Holdings, Inc.'s radiosensitizers. If local control is already good with radiation-only protocols, physicians may skip the added agent, especially when budgets are tight. That keeps substitute pressure high in cost-sensitive oncology care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOther cancer drug classes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunotherapies, targeted therapies, and chemotherapy are direct substitutes for Shuttle Pharmaceuticals Holdings, Inc.’s radiation-enhancing agents, and they are already standard care across many cancers.\u003c\/p\u003e\n\u003cp\u003eIf these drugs improve survival or quality of life, oncologists may choose them first, which cuts demand for Shuttle Pharmaceuticals Holdings, Inc.’s products.\u003c\/p\u003e\n\u003cp\u003eThat means Shuttle Pharmaceuticals Holdings, Inc. must prove clear added benefit versus these established classes, not just clinical overlap.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Substitutes-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlternative combination regimens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlternative combination regimens keep substitute pressure high for Shuttle Pharmaceuticals Holdings, Inc., because oncologists can add other radiosensitizers, immunotherapies, or supportive drugs to boost radiation response. More than 50% of cancer patients receive radiotherapy, so even small gains from rival add-ons matter at scale. As similar outcomes appear across competing regimens, Shuttle’s pricing power and trial differentiation get squeezed.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLocal control procedures\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eLocal control procedures remain a strong substitute because surgery, ablation, and related localized treatments can be preferred for eligible tumors, avoiding systemic drug exposure. The NCI projects about 2.0 million new U.S. cancer cases in 2026, and a large share of early-stage solid tumors are managed with local therapy first, which narrows Shuttle Pharmaceuticals Holdings, Inc.'s drug-based radiosensitization pool.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower drug need in localized disease\u003c\/li\u003e\n\u003cli\u003ePreferred when systemic toxicity matters\u003c\/li\u003e\n\u003cli\u003eMost pressure in early-stage tumors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eWatchful waiting or palliative care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIn advanced or fragile patients, watchful waiting or palliative care can replace aggressive combination therapy when the expected benefit is unclear. For Shuttle Pharmaceuticals Holdings, Inc., this matters because high drug prices and added toxicity can push doctors and patients toward symptom control instead of a new cancer regimen.\u003c\/p\u003e\n\u003cp\u003eThis substitute gets stronger when treatment adds side effects without clear survival gain. If a therapy is seen as costly, harsh, or uncertain, conservative care becomes the practical choice.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSymptom relief can beat uncertain benefit\u003c\/li\u003e\n\u003cli\u003eToxicity raises the switch to palliative care\u003c\/li\u003e\n\u003cli\u003eHigh prices make conservative care more attractive\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eShuttle Faces Strong Substitute Pressure in Cancer Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of substitutes is high for Shuttle Pharmaceuticals Holdings, Inc. because radiation-only care, surgery, ablation, chemo, immunotherapy, and palliative care can all replace a radiosensitizer. With 2.0 million U.S. cancer cases projected for 2026 and over 50% of patients receiving radiotherapy, the pool is large but rivalry for each case is intense.\u003c\/p\u003e\n\u003cp\u003eWhen rivals offer equal or better survival, lower toxicity, or lower cost, doctors can skip Shuttle Pharmaceuticals Holdings, Inc.'s add-on drug. That keeps pricing power weak and raises proof demands.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSubstitute\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRadiation alone\u003c\/td\u003e\n\u003ctd\u003eNo add-on drug needed\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSurgery or ablation\u003c\/td\u003e\n\u003ctd\u003eRemoves need for systemic therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImmunotherapy and chemo\u003c\/td\u003e\n\u003ctd\u003eOften chosen first\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEntrants Threaten\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh regulatory barrier\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eShuttle Pharmaceuticals Holdings, Inc. faces a high regulatory moat because oncology drugs usually need 3 clinical phases, FDA review, and large safety datasets before approval. In oncology, development often takes 8-12 years and can cost over $1 billion, which pushes out casual entrants. That makes regulation one of Shuttle Pharmaceuticals Holdings, Inc.’s strongest defenses against new competitors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy capital requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHeavy capital needs make Shuttle Pharmaceuticals Holdings, Inc. hard to challenge. Drug trials can run 6-10 years and often cost well over $100 million, while GMP manufacturing and FDA filings add more cash burn before revenue starts. That long funding gap raises the bar for new entrants and slows fast market entry.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/5FORCES-Content-Entrants-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIP and know-how barriers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatent protection, formulation know-how, and clinical experience are major barriers in specialty oncology. Shuttle Pharmaceuticals Holdings, Inc. has spent years building radiosensitizer expertise, and new firms without strong IP or translational skills would struggle to match that path. The result is a real entry barrier, because copying the science is far harder than funding it.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific collaboration channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eScientific collaboration channels keep entry risk real: university labs can spin out startups once radiation-sensitizing data is published and licensed. Outside capital can fund an entrant fast, so Shuttle Pharmaceuticals Holdings, Inc. faces high but not sealed barriers. The gate is IP, know-how, and trial cost, but academic disclosure still opens the door.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUniversity licenses can seed spinouts\u003c\/li\u003e\n\u003cli\u003ePublished data can draw VC funding\u003c\/li\u003e\n\u003cli\u003eIP and trials still slow new entrants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership access matters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNew entrants need 3 hard-to-copy links: hospital access, trial networks, and GMP manufacturing partners. That slows Shuttle Pharmaceuticals Holdings, Inc. rivals because site selection, sponsor trust, and supply setup usually take years, not months. Even with attractive science, weak partnerships delay scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 partner types block fast entry\u003c\/li\u003e\n\u003cli\u003eHospital ties are hard to copy\u003c\/li\u003e\n\u003cli\u003eTrial access speeds or slows launches\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Barriers Keep New Entrants Out of Shuttle Pharma’s Oncology Niche\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThreat of new entrants for Shuttle Pharmaceuticals Holdings, Inc. stays high but not open: oncology drug paths often take 8-12 years, cost over $1 billion, and need FDA approval plus GMP manufacturing. Still, university licenses and published radiosensitizer data can seed spinouts fast. So IP, clinical access, and capital remain the main gatekeepers.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBarrier\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment time\u003c\/td\u003e\n\u003ctd\u003e8-12 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProgram cost\u003c\/td\u003e\n\u003ctd\u003eOver $1 billion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial cost\u003c\/td\u003e\n\u003ctd\u003eWell over $100 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234976669961,"sku":"shph-five-forces","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/shph-five-forces.webp?v=1785731493","url":"https:\/\/dcfanalyst.com\/products\/shph-five-forces","provider":"DCF Analyst","version":"1.0","type":"link"}